KRAS and non-small cell lung carcinoma: It should be noted that the outcome of KRAS-mutant treatments is dominated by co-occurring genetic events, as STK11/LKB1 and KEAP1 mutations define a subset of “cold” NSCLC resistant to ICI, while TP53 alterations increase the inflammatory microenvironment, leading to an efficient immune response.